2016 Jeffrey M. Hoeg Award Lecture
Overview
Authors
Affiliations
Innate and adaptive immune effector mechanisms, in conjunction with hyperlipidemia, are important drivers of atherosclerosis. The interaction between the different immune cells and the secretion of cytokines and chemokines determine the progression of atherosclerosis. The activation or dampening of the immune response is tightly controlled by immune checkpoints. Costimulatory and coinhibitory immune checkpoints represent potential targets for immune modulatory therapies for atherosclerosis. This review will discuss the current knowledge on immune checkpoints in atherosclerosis and the clinical potential of immune checkpoint targeted therapy for atherosclerosis.
Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).
PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.
Nitz K, Herrmann J, Lerman A, Lutgens E JACC Basic Transl Sci. 2024; 9(6):827-843.
PMID: 39070270 PMC: 11282889. DOI: 10.1016/j.jacbts.2023.12.007.
The emerging role of Th1 cells in atherosclerosis and its implications for therapy.
Chen J, Xiang X, Nie L, Guo X, Zhang F, Wen C Front Immunol. 2023; 13:1079668.
PMID: 36685487 PMC: 9849744. DOI: 10.3389/fimmu.2022.1079668.
B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications.
Pattarabanjird T, Li C, McNamara C JACC Basic Transl Sci. 2021; 6(6):546-563.
PMID: 34222726 PMC: 8246059. DOI: 10.1016/j.jacbts.2021.01.006.
Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease.
Lacy M, Burger C, Shami A, Ahmadsei M, Winkels H, Nitz K Nat Commun. 2021; 12(1):3754.
PMID: 34145241 PMC: 8213756. DOI: 10.1038/s41467-021-23909-z.